Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study

Gullo, Lucio; Migliori, Marina; Falconi, Massimo; Pederzoli, Paolo; Bettini, Rossella; Casadei, Riccardo; Delle Fave, Gianfranco; Corleto, Vito D.; Ceccarelli, Claudio; Santini, Donatella; Tomassetti, Paola
November 2003
American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2435
Academic Journal
: ObjectivesNonfunctioning pancreatic endocrine tumors (NFPTs) are rare neoplasms that have been the object of few studies that have involved only small numbers of patients. This study was carried out to obtain a comprehensive and up-to-date clinical picture of these tumors.: MethodsA total of 184 patients with NFPT admitted to three Italian hospitals in the last 15 yr were studied. The diagnosis of NFPT was confirmed histologically using conventional and immunohistochemical techniques. Data were obtained from the medical charts or directly from the patients.: ResultsThere were 85 men (46.2%) and 99 women (53.8%). The mean age at diagnosis was 55.2 yr (range 17–82 yr). The percentage of smokers and alcohol drinkers was similar to that in the general population. Seven patients (3.9%) had a family history of exocrine pancreatic carcinoma. In 120 cases (65.2%), the diagnosis was made after workup for pain or other symptoms, in the remaining 64 cases (34.8%), the tumor was discovered incidentally by ultrasound; in this group survival was significantly greater than it was for the symptomatic patients (p = 0.0043). Survival was also found to be improved by tumor resection (p < 0.0001), absence of metastases (p < 0.0001), and small tumor size (≤3 cm) (p < 0.0007).: ConclusionsNFPTs were slightly more frequent in women and were diagnosed most often in middle-aged individuals. No risk factors other than a family history of exocrine pancreatic carcinoma were found. Tumor discovery while patients were still asymptomatic, tumor resection, absence of metastases, and tumor size ≤3 cm significantly prolonged survival.


Related Articles

  • High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Weichert, W.; Boehm, M.; Gekeler, V.; Bahra, M.; Langrehr, J.; Neuhaus, P.; Denkert, C.; Imre, G.; Weller, C.; Hofmann, H.-P.; Niesporek, S.; Jacob, J.; Dietel, M.; Scheidereit, C.; Kristiansen, G. // British Journal of Cancer;8/20/2007, Vol. 97 Issue 4, p523 

    Activation of nuclear factor-κB (NF-κB) signaling was observed in pancreatic adenocarcinoma cell lines and tumours. However, information on the expression of RelA/p65, the major transcription activating NF-κB subunit, in these carcinomas and possible correlations thereof with NF-κB...

  • A Rare Case of Metachronous Skip Metastasis of Pancreatic Cancer to the Colon. Ogu, Uchechukwu Stanley; Bloch, Robert; Park, Grace // American Surgeon;Jul2012, Vol. 78 Issue 7, pE342 

    The article describes a rare case of metachronous skip metastasis of pancreatic cancer to the colon in an 85-year-old woman. The patient, who has a medical history of Stage IIA pancreatic cancer, status postpancreaticoduodenectomy, was presented with a 1-week history of constipation and...

  • miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Iwagami, Y; Eguchi, H; Nagano, H; Akita, H; Hama, N; Wada, H; Kawamoto, K; Kobayashi, S; Tomokuni, A; Tomimaru, Y; Mori, M; Doki, Y // British Journal of Cancer;7/23/2013, Vol. 109 Issue 2, p502 

    Background:Gemcitabine-based chemotherapy is the standard treatment for pancreatic cancer. However, the issue of resistance remains unresolved. The aim of this study was to identify microRNAs (miRNAs) that govern the resistance to gemcitabine in pancreatic cancer.Methods:miRNA microarray...

  • Salivary MicroRNA in Pancreatic Cancer Patients. Humeau, Marine; Vignolle-Vidoni, Alix; Sicard, Flavie; Martins, Frédéric; Bournet, Barbara; Buscail, Louis; Torrisani, Jérôme; Cordelier, Pierre // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Pancreatic cancer is the fourth leading cause of cancer death in Western countries, with the lowest 1-year survival rate among commonly diagnosed cancers. Reliable biomarkers for pancreatic cancer diagnosis are lacking and are urgently needed to allow for curative surgery. As...

  • Smaller tumors at diagnosis improved pancreatic cancer survival.  // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p40 

    The article reports that a retrospective study showed smaller tumors increased pancreatic cancer survival during diagnosis. It details the study of the University of Texas M.D. Anderson Cancer Center and Saint Louis University that included 65 consecutive pancreatic cancer patients who have...

  • ‘One also needs a bit of trust in the doctor … ’: a qualitative interview study with pancreatic cancer patients about their perceptions and views on information and treatment decision-making. Schildmann, J.; Ritter, P.; Salloch, S.; Uhl, W.; Vollmann, J. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2444 

    Background Information about diagnosis, treatment options and prognosis has been emphasized as a key to empower cancer patients to make treatment decisions reflecting their values. However, surveys indicate that patients' preferences regarding information and treatment decision-making differ. In...

  • Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. Lin, Mao; Yuan, Yuan-Ying; Liu, Shu-Peng; Shi, Juan-Juan; Long, Xin-An; Niu, Li-Zhi; Chen, Ji-Bing; Li, Qiao; Xu, Ke-Cheng // Journal of Cancer Research & Clinical Oncology;Oct2015, Vol. 141 Issue 10, p1827 

    Introduction: In this trial, we isolated and cultured pancreatic cancer stem cells (CSCs) to produce a vaccine and prospectively evaluated its safety and efficacy in low-, medium-, and high-dose groups. Material and methods: Between February and October 2014, we enrolled 90 patients who met the...

  • Implications and issues related to familial pancreatic cancer: a cohort study of hospitalized patients. Mughetti, Martina; Calculli, Lucia; Chiesa, Anna Maria; Ciccarese, Federica; Rrusho, Odeta; Pezzilli, Raffaele // BMC Gastroenterology;1/15/2016, Vol. 16, p1 

    Background: The surveillance of subjects at risk of pancreatic cancer is restricted to clinical research; the incidence of familial pancreatic cancer needs to be better established. Thus, we aimed to evaluate the frequency of familial pancreatic cancer in a population of...

  • The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Yan Chen; Jing Sun; Hua Zhao; Dongming Zhu; Qiaoming Zhi; Shiduo Song; Lifeng Zhang; Songbing He; Yuting Kuang; Zixiang Zhang; Dechun Li // OncoTargets & Therapy;Aug2014, Vol. 7, p1465 

    Aim: We investigated the expression of the inhibitory costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer to define their clinical significance and mechanism in a tumor microenvironment. Patients and methods: Sixty-three pancreatic cancer tissues and 12 normal pancreatic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics